New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 7, 2017 – The FDA announced the approval of Emmaus Medical’s Endari (L-glutamine), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients ≥ 5 years of age.
Download PDF
Return to publications
